Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer (CMO). Dr. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, Cassava’s investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy.

Read more at globenewswire.com